News | January 28, 2023
Bliss GVS Pharma posts Q3 FY23 consolidated PAT at Rs. 27.94 Cr
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Cell sorting technology supports researchers advancing new therapies
Medical Tourism will boost India’s economy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
